A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Trial Profile

A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Bortezomib (Primary) ; Vorinostat (Primary) ; Crisantaspase; Doxorubicin; Hydrocortisone; Mercaptopurine; Methotrexate; Mitoxantrone; Pegaspargase
  • Indications Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Jan 2017 Planned End Date changed from 1 Apr 2029 to 1 Oct 2026.
    • 05 Jan 2017 Status changed from recruiting to discontinued as accrual goals were no longer feasible based on restrictions imposed by the DSMB.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top